Diabetic Neuropathy Drug Development Services
Diabetic neuropathy (DN) is one of the most prevalent and debilitating complications of diabetes, affecting up to 50% of people worldwide. Characterized by peripheral nerve damage, it leads to pain, sensory loss, motor dysfunction, and increased risk of foot ulcers or amputations. Despite significant research efforts, effective therapies remain limited, leaving a critical unmet medical need. As a preclinical CRO specializing in diabetes, Ace Therapeutics is dedicated to accelerating DN therapy development with tailored, translatable preclinical solutions that support biotech, pharma, and research institutions from target validation through preclinical candidate selection.
Current Status and Challenges in Diabetic Neuropathy Drug Development
The path to successful DN therapy is hindered by unique obstacles that demand specialized preclinical expertise:
- Complex Pathophysiology: DN involves interconnected mechanisms (oxidative stress, inflammation, nerve fiber degeneration, and metabolic dysfunction) that require multi-dimensional evaluation.
- Translatability Gaps: Traditional animal models often fail to recapitulate human DN's heterogeneity, leading to high clinical trial failure rates.
- Lack of Validated Biomarkers: Identifying reliable biomarkers for early detection, efficacy assessment, and patient stratification remains a major challenge.
- Limited Efficacy Endpoints: Quantifying sensory/motor improvements in preclinical models requires sensitive, clinically relevant readouts.
Our Diabetic Neuropathy Drug Development Services
We offer a comprehensive suite of preclinical services tailored to address DN therapy development needs, from target discovery to preclinical proof-of-concept:
- Target Validation: In vitro and in vivo validation of DN-related targets (e.g., neuroprotective pathways, anti-inflammatory molecules) using disease-relevant models.
- Customized Animal Model Development: Induction of DN in rodent models (streptozotocin-induced, high-fat diet-induced, or genetic models) with phenotypic characterization matching human pathology.
- Pharmacodynamic (PD) Efficacy Evaluation: Behavioral (pain threshold, motor function), electrophysiological (nerve conduction velocity), and histological (nerve fiber density, axonal integrity) assessments.
- Safety Pharmacology: Evaluation of potential neurotoxicity, off-target effects, and tolerability in DN models.
- Biomarker Discovery & Validation: Identification of lipidomic, metabolomic, or transcriptomic biomarkers to support efficacy monitoring and clinical translation.
Advanced Technology Platforms
Our services are powered by cutting-edge platforms designed to enhance translatability and data reliability:
- Precision DN Animal Models: Phenotypically validated models with reproducible nerve damage, sensory deficits, and metabolic abnormalities.
- High-Resolution Electrophysiology: State-of-the-art equipment for measuring nerve conduction velocity, compound action potentials, and synaptic function.
- Multi-Omics Analysis: Integrated lipidomics, metabolomics, and transcriptomics platforms to decode molecular mechanisms and identify biomarkers.
- 3D In Vitro Nerve Models: Human-derived 3D neural cultures to mimic peripheral nerve microenvironments, enabling early-stage target screening.
- Advanced Imaging: Confocal microscopy and immunohistochemistry for quantitative analysis of nerve fiber density, inflammation, and axonal regeneration.
Ace Therapeutics is dedicated to providing our clients with one-stop preclinical services for diabetic neuropathy therapy development. Contact our neuropathy experts today to discuss your specific program needs and request a custom project proposal.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
